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Shai Yarkoni,1 Tatyana B. Prigozhina,2 Shimon Slavin,3 Nadir Askenasy4T cell depletion prevents graft-versus-host disease (GVHD) but also removes T cell-mediated support of
hematopoietic cell engraftment. A chimeric molecule composed of IL-2 and caspase-3 (IL2-cas) has been
evaluated as a therapeutic modality for GVHD and selective ex vivo depletion of host-reactive T cells. IL2-
cas does not affect hematopoietic cell engraftment and significantly reduces the clinical and histological
severity of GVHD. Early administration of IL2-cas reduced the lethal outcome of haploidentical trans-
plants, and survivor mice displayed markedly elevated levels of X-linked forkhead/winged helix (FoxP31;
50%) and CD251FoxP31 T cells (35%) in the lymph nodes. The chimeric molecule induces in vitro
apoptosis in both CD41CD252 and CD41CD251 subsets of lymphocytes from alloimmunized mice,
and stimulates proliferation of cells with highest levels of CD25 expression. Adoptive transfer of IL2-
cas–pretreated viable splenocytes into sublethally irradiated haploidentical recipients resulted in 60%
survival after a lethal challenge with lipopolysaccharide, which is associated with elevated fractions of
CD25highFoxP31 T cells in the lymph nodes of survivors. These data demonstrate that ex vivo purging
of host-presensitized lymphocytes is effectively achieved with IL2-cas, and that IL-2–targeted apoptotic
therapy reduces GVHD severity in vivo. Both approaches promote survival in lethal models of haploident-
ical GVHD. The mechanism of protection includes direct killing of GVHD effectors, prevention of transi-
tion to effector/memory T cells, and induction of regulatory T cell proliferation, which becomes the
dominant subset under conditions of homeostatic expansion.
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Regulatory T cellINTRODUCTION
T cells have dual beneficial function in bone mar-
row transplantation: support of hematopoietic progen-
itor engraftment and immunotherapy. For effective
implementation of T cell-mediated activities, it is es-
sential to reduce and/or abrogate the potentially lethal
graft-versus-host disease (GVHD). The activation and
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6/j.bbmt.2011.11.016due to propagation of cytokine cascades superposed
on injury caused by pretransplantation conditioning,
resulting in severe tissue damage and often a fatal out-
come [1-3]. Most clinical approaches use extensive
depletion of T cells and sometimes B lymphocytes
from donor inoculum [4-6], particularly when cells
are collected from mobilized peripheral blood and in
haploidentical transplants. More recent approaches
use selective depletion of host-reactive donor T cells
ex vivo to eliminate clones endowed with GVHD
potential. Repeated TCR engagement induces IL-2–
dependent cell proliferation and concomitant sensiti-
zation to apoptosis [7]. Based on the physiological
process of T cell activation, selective depletion has
been attained targeting Fas [8-10], the IL-2 receptor
[11-15], and proliferating cells [16]. Identification of
the high-affinity a-chain of the IL-2 receptor
(CD25) as a reliable target in alloreactive T cells [17]
led to implementation of immunomagnetic separation
of activated T cells based on phenotype [11,12], along
with a number of fusion proteins that target the IL-2
receptor to deliver toxic moieties for selective killing
of potential GVHD effectors. Anti-CD25 antibodies523
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lated ricin toxin-A chain [12,14,15] have shown
superior efficacy in preventing GVHD compared with
diphtheria toxin fused to IL-2 in depleting CD251
reactive T cells [12]. In addition to several promising
clinical trials using selective depletion of host-reactive
T cells ex vivo by targeting the IL-2 receptor [18-21],
anti-CD25 monoclonal antibodies have been applied
forGVHDprophylaxis in allogeneic andhaploidentical
transplantations [22-24].
In view of the significant role of IL-2 in immune
reconstitution after transplantation [25], with particu-
lar efficacy in anticancer immunotherapy [26], thera-
peutic approaches to GVHD based on neutralization
of the effects of IL-2 might impede transplantation
outcomes and exacerbate GVHD [27]. Furthermore,
approaches based on specific targeting of the IL-2 re-
ceptor raise questions regarding the effects on regula-
tory T cell (Treg) homeostasis. Naturally occurring
Tregs are characterized by high-level expression of
CD25 and the associated transcription factor X-linked
forkhead/winged helix (FoxP3), making this subset ex-
tremely susceptible to IL-2– and IL-2– receptor-
targeted therapy. On the one hand, adoptive transfer
of donor Tregs protects from lethal GVHD without
impairing graft-versus-tumor (GVT) reactivity
[28-33]. Consistently, IL-2–dependent expansion of
host Tregs suppresses GVHD while retaining GVT
activity [34] and ameliorates host-versus-graft (HVG)
resistance [35]. On the other hand, adoptive transfer
of naturally occurring Tregs negatively affects the en-
graftment of hematopoietic progenitors [36]. It re-
mains to be determined whether, similar to different
subsets of na€ıve/effector T cells [37], selective protec-
tion from GVHD can be dissociated from suppression
of engraftment based on phenotypic and/or functional
characteristics of Tregs.
We have tested a chimeric molecule composed of
IL-2 as a targeting moiety and caspase-3 to activate
the intrinsic apoptotic pathway (IL2-cas). This conju-
gate was demonstrated effective in blunting the patho-
genesis of 2 model disorders characterized by relative
resistance of pathogenic cells to apoptosis: inflamma-
tory bowel disease [38] and autoimmune insulitis
[39]. Although targeting the IL-2 receptor has partic-
ular affinity for Treg depletion, an interesting immu-
nomodulatory feature of the chimeric protein is
a marked elevation in CD41FoxP31 T cells, a hetero-
geneous population that includes precursors of both
effector and regulatory subsets [40]. In this study,
IL2-cas was used in 2GVHDmodels: posttransplanta-
tion therapy and prevention by pretransplantation
ex vivo deletion of host-sensitized donor lymphocytes.
In both models, IL2-cas proved effective in preventing
lethal GVHD, and, moreover, the particular mode of
action of this chimeric protein resulted in expansion
of suppressor subsets.MATERIALS AND METHODS
Animal Preparation and Disease Model
BALB/c (H2Kd), C57BL/6J (B6, H2b, CD45.2),
B6.SJL-Ptprca Pepcb/BoyJ (H2Kb, CD45.1), and
C57BL/6-TgN(ACTbEGFP)1Osb (GFP, H2kb,
CD45.2)mice were purchased from Jackson Laborato-
ries (Bar Harbor, ME) and housed in a barrier facility.
F1 chimeras (H2Kb/d, CD45.2) were inbred from
C57BL/6 and BALB/c mice. The Institutional Animal
Care Committee of the BeilinsonCampus approved all
procedures. Recipients were conditioned by sublethal
doses of total body irradiation (550-700 rad) using an
X-ray irradiator (RadSource 2000; Rad Source Tech-
nologies, Suwanee, GA) at a rate of 106 rad/min. Irra-
diation was routinely performed 18-24 hours before
transplantation. (Of note, X-ray irradiation has a lower
myeloablative dose and greater toxicity compared with
g irradiation.) For transplantation, cells suspended in
0.2 mL of PBS were infused into the lateral tail vein.
Agents
IL-2 conjugated to truncated diphtheria toxin (de-
nileukin diftitox; Ontak) was purchased from Seragen
(San Diego, CA). IL2-cas is composed of full-frame
IL-2 conjugated head to tail to full-frame caspase-3
(without the leading procaspase segment) [38,39].
The sequence was inserted into a PET-28 plasmid un-
der control of the T7 promoter, and protein retrieved
from the inclusion bodies of Escherichia coliwas purified
under denatured conditions and refolded to a biologi-
cally active molecule.
Cell Preparation
Whole bone marrow cells (BMCs) were harvested
from femurs and tibia in PBS (Beit Haemek, Israel) un-
der aseptic conditions [41]. T cell depletion was per-
formed immunomagnetically by incubating the cells
for 45 minutes at 4C with saturating amounts of rat
anti-mouse mAbs specific for CD4, CD5, and CD8
(harvested from hybridoma cell lines). The antibody-
coated cells were washed twice with PBS containing
1% FCS (Biological Industries, Kibutz Haemek,
Israel) and incubated with sheep anti-rat IgG conju-
gated to M-450 magnetic beads (Dynal, Lake Success,
NY), with 4 beads per cell. T cell–depeleted (TCD)
BMCs were collected by exposure to a magnetic field,
and the efficiency of separation was reassessed by flow
cytometry using FITC-labeled mAbs against these
markers (eBioscience, San Diego, CA and BD Phar-
mingen, Erembodegem, Belgium).To achieve a higher
degree of purity (.95%), the immunomagnetic sepa-
ration was repeated in some cases.
Spleens and lymph nodes were harvested and
gently minced on a 40-mM nylon mesh in HBSS
(Beit Haemek) to prepare single-cell suspensions
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obtain single-cell suspensions. For flow cytometry, the
red cells were removed by ammonium chloride lysis
for 4 minutes at room temperature. The reaction was
arrested with excess ice-cold solution, and cells were
washed. For proliferation assays, the lymphocytes
were centrifuged over 1.5 mL of lymphocyte separa-
tion media (Cedarlane, Ontario, Canada). Cell death
was assayed by the trypan blue exclusion test to show
.90% viability in all samples.
GVHD Model
F1 chimeras (H2Kb/d, CD45.2) were sublethally
irradiated and transplanted after 18 hours (day 0)
with semiallogeneic BMCs (H2KbCD45.1) and sple-
nocytes (H2KbGFP1). A calibration curve for lethal
GVHD was calculated to determine the number of
donor haploidentical splenocytes required to induce
lethal GVHDunder our experimental conditions. Dis-
ease severity was scored using weight loss and a semi-
quantitative clinical 0-4 scale including posture (ie,
hyperkeratosis of the foot pads), diffuse erythema (par-
ticularly of the ear) or dermatitis (including hair loss),
diarrhea, and activity [42,43]. At the experimental
endpoint, ear edge biopsy specimens and livers
were harvested and fixed in 4% paraformaldehyde.
Cryosections were stained with H & E and inspected
using a Zeiss Axioplan 2 microscope (Carl Zeiss,
Oberkochen, Germany). Histological scoring was done
using the following scale: 0, no infiltration; 1, scarce
infiltrates; 2, patchy infiltration; 3, diffuse infiltration;
4, deterioration of tissue infrastructure [43].
Flow Cytometry
Cells were labeled by incubation for 45 minutes at
4C with the appropriate antibodies conjugated to
FITC, PE, allophycocyanin, and peridinin chlorophyll
a-protein (BD Pharmingen): CD4 (clone RM 4-5),
CD8 (clone 53-6.7), and CD25 (clone BC96) [41].
FoxP3 was measured after permeabilization and intra-
cellular staining with a PE-labeled antibody (Foxp3
staining buffer set NRRF-30; eBioscience) [38,39].
Antibodies were purchased from BD Pharmingen
and eBioscience. Donor chimerism in syngeneic
transplants was determined from the percentage of
donor and host peripheral blood lymphocytes using
monoclonal antibodies against minor antigens
CD45.1 (clone A20; eBioscience) and CD45.2 (clone
104; eBioscience), respectively. Donor chimerism in
allogeneic transplants was determined using PE-anti-
H2Kb (clone CTKb; Caltag, Burlingame, CA) and
FITC anti-H2Kd mAb (clone SF-1.1; BD Pharmin-
gen). Cell death and apoptosis were determined in cells
incubated with 5 mg/mL of 7-aminoactinomycin-D (7-
AAD; Sigma-Aldrich, St. Louis, MO) and Annexin-V
(IQ Products, Groningen, the Netherlands).Measurements were performed with a Vantage SE
flow cytometer (BD, Franklin Lakes, NJ). Positive
staining was determined on a log scale, normalized
with control cells stained with isotype control anti-
bodies.
In Vitro Apoptosis
In this procedure, 2 106 cells/mLwere incubated
in DMEM supplemented with 2 mM L-glutamine,
1 mM sodium pyruvate, 13.6 mM folic acid, 270 mM
L-asparagine, 548 mM L-arginine HCL, 10 mM
HEPES, 50 mM 2b-mercaptoethanol, 100 mg/mL
streptomycin, 100 U/mL penicillin, and 5% heat-
inactivated FBS (MLR medium) [44]. All ingredients
were purchased from Beit Haemek and Sigma-
Aldrich. Apoptotic challenge was applied by the addi-
tion of 2 mg/mL of IL2-cas fusion protein.
Proliferation Assay
Cells were plated in plastic dishes (5 107), and af-
ter 45 minutes, the nonadherent lymphocytes were
collected and washed [38,39]. The lymphocytes were
incubated at room temperature for 7 minutes with
10 mM 5-(and 6-)-carboxyfluorescein diacetate
succinimidyl ester (CFSE; Molecular Probes,
Eugene, OR), followed by arresting of labeling by the
addition of 50% FCS and washing with PBS. Stained
cells were cultured at a density of 106/mL in MLR
medium in a humidified 5% CO2 atmosphere at 37
C
for 3 days, then stimulated with 5 mM concanavalin A
(ConA, Sigma-Aldrich). All proliferation assays were
performed in triplicate and related to unstimulated
cells. CFSE dilution was analyzed by flow cytometry
with gating on the live lymphocytes, and proliferation
was quantified usingModFit software (Verity Software
House, Topsham, ME).
Statistical Analysis
Data are presented as mean 6 standard deviation
for each experimental protocol. Differences between
the experimental results were estimated with a post
hoc Scheffe t test, and survival curves were assessed
the using Mantel-Cox test, with a threshold signifi-
cance of P \ .05. Statistical processing of survival
was performed using BMDP software.RESULTS
IL-2–Targeted Therapy Protects Against GVHD
In the first set of experiments, we assessed the ther-
apeutic efficacy of IL2-cas in a haploidentical model
(H2Kb/H2Kb/d) of lethal GVHD induced by infu-
sion of 107 BMCs and 3  107 parent lymphocytes
into sublethally irradiated (700 rad total body irradia-
tion [TBI]) F1 recipients (Figure 1A). The recipients
Figure 1. IL2-cas ameliorates the course of GVHD in vivo. (A) A haploidentical murinemodel of GVHDwas established by transplantation of 107 BMCs
and 3 107 splenocytes (day 0) into sublethally irradiated (700 rad) F1 recipients (H2Kb/H2Kb/d). IL2-cas was administered at daily doses of 1 mg/g for
3 weeks and then 2 mg/g at 2-day intervals for 4 weeks, starting on day 0 (protocol 1A) or day16 (protocol 1B). (B) Impact of early (day 0) therapy with
IL2-cas (n5 11) and 2 mg/g anti-CD25 antibodies (n5 10) and late IL2-cas therapy (day16; n5 11) compared with untreated mice (GVHD; n5 12).
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time of 17.36 2 days, which was insignificantly atten-
uated by daily administration of 2 mg/g of anti-CD25
antibodies (mean survival, 21 6 6.5 days; Figure 1B).
In contrast, initiation of therapy with 1 mg/g of IL2-
cas at the time of transplantation resulted in superior
survival (protocol 1A; P 5 .017 versus GVHD con-
trol), which was less pronouncedwhen IL2-cas therapy
was initiated in mice with established disease (protocol
1B; P 5 .038 versus GVHD control). Consistent vari-
ations in body weight (Figure 1C) indicate that pro-
phylactic therapy with IL2-cas is more effective than
treatment of established disease.
One of the consequences of severe GVHD is sup-
pression of donor cell engraftment and decreased levels
of chimerism [45,46]. Mice that survived for 7 weeks
showed reduced levels of donor cells in peripheral
blood (P\ .01; Figure 1D), followed by an increase
at 11 weeks posttransplantation. Of note, there were
no significant differences in the donor and host mye-
loid/lymphoid ratio in peripheral blood ofmice among
the various experimental groups. Further analysis of
the peripheral lymphoid organs at the end of the ex-
periment revealed insignificant variations in the num-
bers of T cells in the spleen (Figure 1E), which was
quantitatively reconstituted at this time point (94 6
11  106 cells, compared with 1046 106 cells in na€ıve
mice). In contrast, the CD41/CD81 ratio was inverted
in the lymph nodes of long-term survivors in both
treatment protocols (Figure 1E). Another common
feature of all treated mice was a significant increase in
the number of CD41CD252FoxP31 T cells in the
spleen (P\ .005 versus na€ıve mice), and marked frac-
tional enrichment in CD41FoxP31 T cells, including
both CD252 and CD251 subsets in the mesenteric
lymph nodes (P \ .001 versus na€ıve mice)
(Figure 1F). Similar profiles of increased fractions of
CD41CD251FoxP31 T cells in peripheral lymphoid
organs were also observed in aGVHDmodel of alloge-
neic bone marrow transplantation (H2Kb/H2Kd).Mechanism of IL-2–Targeted Therapy
Protection from lethal GVHD by IL2-cas therapy
and the extensive variations in immune profiles ques-
tioned the mechanism of action of this fusion protein.
IL2-casmight enhance engraftment, generating a large
pool of T cells tolerant to the host that compete with
the GVHD effectors [43,47], target the GVHD
effectors [12-15], or amplify suppressor subsetsThe data summarize 2 experiments, each including all experimental groups. (
groups. (D) Donor chimerism in peripheral blood at 7 weeks (end of therapy
and T cells in recipients of early (n 5 5) and late (n 5 4) therapy. Chimeris
(E and F) Immune profiles of survivors of early (n 5 5) and late (n 5 2) the
and CD81 T cells in the spleen and mesenteric lymph nodes presented as p
CD25 and FoxP3 in the spleen (left), representative plots of CD25 and FoxP3
FoxP3 expression in CD41 T cells in the mesenteric lymph nodes (right).
=[29,30]. To evaluate whether IL2-cas augments hema-
topoietic cell engraftment, it was compared with the
immunosuppressive activity of cyclophosphamide
[42,48] in a modified model adopted from clinical
studies [23,24]. Sublethally irradiated BALB/c mice
(550 rad TBI) were engrafted with 5  106 TCD
BMCs from B6 donors (H2Kb/H2Kd), and 2 doses
of adjuvant chemotherapy were administered on days
0 and 12 (Figure 2A). Administration of 2 doses of
2 mg/g IL2-cas on days 0 and 12 had an insignificant
effect on donor chimerism, whereas cyclophospha-
mide promoted engraftment to full donor chimerism
by 3 weeks posttransplantation (Figure 2B). All mice
survived the transplantation procedure, and both con-
trol and IL2-cas–treated mice progressed to full donor
chimerism at 16 weeks posttransplantation. These
results indicate that IL2-cas neither improves nor
impairs hematopoietic cell engraftment and durable
chimerism, suggesting that the decreased chimerism
at 7 weeks posttransplantation (Figure 1D) was related
mainly to GVHD, not to IL2-cas therapy.
We next assessed the activity of IL2-cas onGVHD
effectors in vivo, in the absence of bone marrow-
derived host-tolerant lymphoid progeny that compete
with the grafted cells [43]. Administration of 2 doses of
4 mg/g IL2-cas (protocol 2) to sublethally irradiated
(650 rad) F1 hosts grafted with 5  106 haploidentical
splenocytes (H2Kb/H2Kb/d) improved survival from
38% in untreated mice (n 5 8) to 70% (n 5 10)
(Figure 2C), and also improved posttransplantion re-
covery of body weight (P\ .001; Figure 2D). Taken
together, these data indicate that the grafted GVHD
effectors are not outcompeted by host-tolerant prog-
eny of the bone marrow graft in the process of
lymphopenia-induced proliferation. The remarkable
effect on the histological GVHD score (Figure 2E)
links IL2-cas with reduced lymphocytic infiltration
in the affected organs, indicating direct targeting of
the GVHD effectors in vivo.
To examine the role of the enriched fractions of
CD252FoxP31T cells observed after IL2-cas therapy
(Figure 1F), we assessed the suppressive function of this
subset in an in vitro proliferation assay. Na€ıve mice
given daily doses of 2 mg/g IL2-cas for 10 days demon-
strated elevated fractions of CD41CD252FoxP31 T
cells (Figure 2F). The FoxP31 subsets were sorted
from the spleens and mesenteric lymph nodes of these
mice in reference toCD25 expression.Coincubation of
both sorted subsets of CD252FoxP31 and
CD251FoxP31 T cells suppressed the proliferationC) Percent changes in body weight of the corresponding experimental
) and 11.5 weeks (experimental endpoint) posttransplantation of BMCs
m was compared with that in mice grafted with BMCs alone (n 5 6).
rapy compared with na€ıve F1 mice (n 5 6). (E) Distribution of CD41
ercentage of total cells. (F) Total numbers of CD41 T cells expressing
expression in gated CD41 subsets (middle), and fractional CD25 and
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(at a 1:1 ratio; Figure 2F). Thus, along with direct tar-
geting of GVHD effectors, IL2-cas has an additional
immunomodulatory activity related to increased frac-
tions of CD252FoxP31 and CD251FoxP31 suppres-
sor subsets.Pretransplantation Depletion of Activated Cells
Protects Against Lethal GVHD
Various approaches to selective depletion of host-
reactive T cells ex vivo have targeted the IL-2 receptor
as an activation marker [11-20], including an IL-2 con-
jugate of diphtheria toxin (Ontak) [12,19]. Reduced
activity of GVHD effectors in vivo suggests that the
fusion proteins might be particularly effective in
depleting host-presensitized GVHD effectors. We re-
capitulated ex vivo depletion of host-sensitized T cells
[18-21] from donors immunized against the host
(Figure 3A) to attain physiological immune stimula-
tion [49]. Adoptive transfer of 1.5  106 H2Kd-sensi-
tized H2Kb splenocytes into sublethally irradiated
(650 rad) haploidentical recipients (H2Kb/d) resulted
in acute GVHD and death of 40% of the mice within
1 week, whereas ex vivo exposure to IL2-cas andOntak
decreased mortality to 10% (Figure 3B). Recipients of
T cells in all experimental groups displayed a similar
fractional distribution of CD41 T cells in peripheral
lymphoid organs, and only recipients of cells pre-
treated with Ontak exhibited lower fractional expres-
sion of CD25 and FoxP3 (Figure 3C). Thus, both
IL-2 conjugates were effective in ameliorating
GVHD,with varying consequences on immune recon-
stitution.
A lipopolysaccharide (LPS) challenge applied on
day17 polarized the survival curves of the experimen-
tal groups; uniform lethality was triggered in recipients
of cells incubated inmedium, whereas 50%-60%of re-
cipients of cells preincubated with IL2-cas and Ontak
survived the challenge (P\ .001; Figure 3D). Assess-
ment of the immune phenotypes on day 12 after
LPS administration revealed several characteristics
associated with acute immune stimulation. LPS-
mediated stimulation induced an apparent redistribu-
tion of CD41T cells from the spleen the lymph nodes,
which was blunted in recipients of selectively depleted
splenocytes (Figure 3E). A reactive increase in CD41
subsets expressing FoxP3 in the mesenteric lymph
nodes of survivors showed marked phenotypicFigure 2. Mechanisms of IL2-cas amelioration of GVHD. (A) Sublethally irrad
doses of adjuvant therapy were administered on days 0 and12. (B) Sublethally
(H2Kb/H2Kd) TCD BMCs (control, n 5 7) and treated with 2 doses of 100
ministered on days 0 and12. Hematopoietic chimerism was measured in perip
(650 rad) F1 recipients were engrafted with 5  106 haploidentical (H2Kb/H
IL2-cas (n5 10). Survival (C) and changes in body weight (D) in the posttranspla
(representative images). (F) B6 mice treated for 10 days with daily doses of 2 mg
The CD252FoxP31 and CD251FoxP31 subsets were sorted and coincubated
assessed from CFSE dilution was quantified with the ModFit software. Data a
=differences in reference to the depleting agent: domi-
nant CD252FoxP31 subset in recipients of medium-
incubated splenocytes (P \ .01) and dominant
CD251FoxP31 subset after IL2-cas depletion (P \
.005) (Figure 3F). Further analysis revealed that
CD41FoxP31 T cells commonly expressed low levels
of CD25 after Ontak pretreatment (P \ .005;
Figure 3F), and only recipients of IL2-cas–pretreated
splenocytes were characterized by high CD25 levels
(P\ .005; Figure 3G). Taken together, these data im-
ply that selective depletion of presensitized splenocytes
improves survival and induces sustained functional dif-
ferences in response to stimulation in vivo, such as
blunted peripheral migration of CD41 T cells.
Compared with depletion with Ontak, depletion with
IL2-cas results in increased fractions of cells with
Treg phenotypes in the survivors.Differential Apoptosis of T Cells Ex Vivo
The consistent enrichment in FoxP31 T cells in-
duced by IL2-cas in both models of ex vivo depletion
of GVHD effectors and in vivo treatment of estab-
lished disease might be caused by survival of this subset
and/or increased proliferation rates. In the first stage
of our analysis, we assessed the apoptotic activity of
IL2-cas during extended incubation for 3 days, which
is generally required for ex vivo depletion of sensitized
lymphocytes [50]. Unlike in shorter incubation periods
[38], apoptosis of CD41CD252/low cells induced by
extended exposure to IL2-cas exceeded that of
CD41CD25high cells (Figure 4A), consistent with in-
ternalization of the fusion protein by other compo-
nents of the IL-2 receptor [51].
In the second stage, our analysis focused on FoxP3
expression, to test whether cells positive for this
transcription factor are less sensitive to apoptosis in-
duced by IL2-cas [38]. The fusion protein had no
significant effect on apoptosis of the CD41CD25low
subset; however, it induced apoptosis preferentially
in CD41CD25high cells lacking FoxP3 expression
(P \ .005; Figure 4B). Superior survival of CD41
CD25highFoxP31 T cells appears to be the basis for
selective enrichment of this subset in treated mice
(Figure 1F) and recipients of cells pretreated with
IL2-cas (Figure 3F-G).
In the third stage, we evaluated whether the fusion
protein induces proliferation, given that its compo-
nents IL-2 and caspase-3 are both known to promoteiated mice (550-650 rad) were grafted with BMCs or splenocytes, and 2
irradiated (550 rad) BALB/c mice were engrafted with 5 106 allogeneic
mg/g cyclophosphamide (n 5 10) or 2 mg/g of IL2-cas (n 5 14) were ad-
heral blood at 3 weeks posttransplantation. (C-E) Sublethally irradiated
2Kb/d) splenocytes (GVHD; n5 8) and treated with 2 doses of 4 mg/g of
ntation period, and histology (E) on day 21 in liver and ear pinna sections
/g IL2-cas displayed a significant increase in CD252FoxP31 subset (left).
with CFSE-loaded CD252 responders at a 1:1 ratio (right). Proliferation
re representative of 3 independent experiments.
Figure 3. Ex vivo exposure of sensitized splenocytes to IL2-cas protects against lethal GVHD. (A) H2Kb mice were immunized with 7  106 H2Kd
splenocytes, and after 1 week spleens were harvested and incubated for 72 hours in medium and with 0.3 mg/mL of Ontak and 2 mg/mL of IL2-cas.
Then 1.5  106 viable splenocytes from the immunized donors were infused into sublethally irradiated (650 rad) F1 (imH2Kb/H2Kb/d) recipients.
(B) Survival of recipients of presensitized splenocytes incubated in medium (GVHD; n 5 17), with Ontak (n 5 12), and with IL2-cas (n 5 14). (C)
Immunophenotype of CD41 T cells in the mesenteric lymph nodes of mice in the corresponding experimental groups (n 5 4). (D) Survival of mice
after i.v. administration of 10 mg of LPS on day 17 after adoptive transfer of cells preincubated in medium (GVHD; n 5 15), with Ontak (n 5 13),
and with IL2-cas (n 5 14). *Mice sacrificed for analysis. (E-G) Immunophenotypes of the spleen and mesenteric lymph nodes at 2 days after LPS
administration to survivors of infusion of cells incubated in medium (n 5 3), with Ontak (n 5 5), and with IL2-cas (n 5 6). (F) Fractional CD25 and
FoxP3 expression within the CD41 subset. (G) Fractions of CD41FoxP31 T cells with low and high CD25 expression.
530 Biol Blood Marrow Transplant 18:523-535, 2012S. Yarkoni et al.cell cycling [52-54]. The fusion protein synergized
with the mitogenic activity of ConA, resulting in
faster proliferation rates of splenocytes in vitro
(Figure 4C). All assays presented here for splenocytes
yielded similar results in cultures of lymph node cells.
Taken together, these data indicate that IL2-cas in-
duces both apoptosis and proliferation in na€ıve/effec-tor and suppressor cells, but is less toxic to CD41 T
cells expressing FoxP3 and high levels of CD25.DISCUSSION
IL2-cas is emerging as an alternative therapeutic
approach to GVHD, both for pretransplantation
Figure 4. Differential apoptosis of T cell subsets ex vivo. C57BL/6mice (H2Kb) were immunizedwith 7 106 BALB/c (H2Kd) splenocytes. After 1week,
splenocytes were incubated for 3 days in medium (control) and with 2 mg/mL of IL2-cas for determination of apoptosis from Annexin-V uptake. Data
represent 5 individual incubations. Apoptosis was determined by gating on CD41 T cells in reference to CD25 expression (A) and in reference to
FoxP3 expression (B). The left panel represents fractional distribution of FoxP3 in the viable CD25low and CD25high subsets. (C) Proliferation index
as determined from CFSE dilution in splenocytes incubated for 3 days in the presence of 5 mg/mL of ConA in medium and with 2 mg/mL of IL2-cas.
Data are representative of 4 independent incubations. CFSE dilution was quantified with the ModFit simulation software compared with the parent signal
(right peak).
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as posttransplantation therapy. The chimeric molecule
targets cells expressing the IL-2 receptor, a ubiquitous
characteristic of activated T cells, and uses a terminal
caspase to simulate the physiological process of
apoptosis. This agent does not induce significant lym-
phopenia under steady-state and disease conditions
[38], and does not perturb the kinetics of hematopoi-
etic cell engraftment and the consequent immune
reconstitution. However, its immunomodulatoryattributes have been shown to ameliorate the course
of GVHD both by apoptotic targeting of effectors
and by triggering the expansion of suppressor subsets.
IL2-cas receptor has been successfully imple-
mented in the treatment of disorders characterized
by relative insensitivity of effector cells to apoptosis,
such as autoimmune insulitis and colitis [38,39].
Direct internalization of caspase-3 by the IL-2 recep-
tor bypasses and overcomes pathways of pathogenic
cell resistance to apoptosis and negative regulation,
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[55-57]. Similarly, in NOD mice, direct elimination
of diabetogenic cells protects against exacerbation of
destructive insulitis by cyclophosphamide, an agent
that selectively depletes Treg subsets [39]. In principle,
a therapeutic approach that targets the IL-2 receptor
as a marker of T cell activation has the capacity to sup-
press both GVHD and HVG resistance mediated by
residual host immune cells after nonmyeloablative
conditioning. We have demonstrated that the fusion
protein reduces the severity of established GVHD
with superior prophylactic efficacy compared with
anti-CD25 antibodies, possibly because antibodies
do not always deplete, but sometimes only inhibit, ef-
fector cell function [58]. Furthermore, the fusion pro-
tein was safely administered over extended periods,
and its immunomodulatory consequences persisted
after discontinuation of therapy. The fusion protein
is also effective in ex vivo selective depletion of host-
presensitized GVHD effectors in stringent haploi-
dentical transplantation models.
Direct cytotoxic activity of IL2-cas in na€ıve/effec-
tor (CD252/low) T cells depends on internalization of
the receptor–ligand complex, which occurs primarily
through the g chain [51]. This component of the
IL-2 receptor is shared by a number of receptors, in-
cluding IL-4, IL-7, IL-9, and IL-15 [59]. Deletion of
host-reactive cells in vitro requires 2-3 days of culture
for the sufficient sensitization of lymphocytes [50] and
for accumulation of intracellular concentrations of the
toxic moiety that causes dose-dependent apoptosis
[39]. Even if the deletion process is not completed
ex vivo, caspase-loaded cells will become apoptotic
and further contribute to Treg expansion and protec-
tion against GVHD [60]. Direct internalization of
toxic moieties, including caspase-3 and diphtheria
toxin, also prevents the accumulation of primed/
memory T cells [61], which are relatively insensitive
to apoptosis because of low levels of caspase-3 [62].
Both CD81 [63] and effector/memory CD4 subsets
[64] are less potent mediators of acute GVHD than
na€ıve T cells; however, these cells are resistant to
receptor-mediated apoptotic signaling and contribute
to chronic GVHD [65,66]. Preventing the transition
to memory phenotypes ex vivo and in vivo explains
the continued suppression of GVH activity after
discontinuation of IL2-cas therapy [67].
The lower cytotoxic activity of caspase-3 com-
pared with diphtheria toxin [38] is a significant advan-
tage in the transplantation setting. On the one hand,
IL2-cas does not cause lymphopenia and thus does
not promote engraftment, and on the other hand,
administration of therapeutic doses does not impair
hematopoietic cell engraftment. This feature is signif-
icant in the reinstitution of immune homeostasis of the
reconstituted lymphoid compartment; Ontak blunted
and IL2-cas promoted the recovery of regulatoryT cell subsets. Reciprocal to suppression of graft func-
tion and immune reconstitution by GVHD [45,46],
prompt repopulation of the lymphoid compartment
has the capacity to counteract GVHD, and early
reinstitution of regulatory mechanisms prevents
uncontrolled expansion of pathogenic effector clones
[68] and induces a state of tolerance [69].
Given the nature of the chimeric protein that tar-
gets of the IL-2 receptor, naturally occurring Tregs
characterized by high-level CD25 expression are
expected to be prime targets of deletion, leading to ex-
acerbation of the immune reaction. Accordingly, apo-
ptosis is effectively induced in significant fractions of
CD251 cells, including naturally occurring FoxP31
Tregs. Although host Tregs are dominant in the early
posttransplantation period [70], the stable levels of do-
nor chimerism indicate that HVG was not amplified
by eliminating suppressor subsets to mediate rejection.
Reciprocally, GVH reactivity was not exacerbated by
CD251 T cell depletion, but rather was suppressed.
Both phenomena are explained based on the dual
mode of action of the chimeric protein, which results
in expansion and relative dominance of Treg pheno-
types in vitro and in vivo. In essence, both constituents
of the chimeric protein are involved in the prolifera-
tion of effector and suppressor T cells [52-54]. Our
data suggest that cells with the highest capacity for
IL-2 uptake are induced to proliferate in vitro, the
likely mechanism of the dominant expansion of the
Treg phenotype in vivo. However, preferential enrich-
ment in CD25high T cells alsomight originate from the
IL-2–mediated signaling through heterodimers of the
IL-2 receptor that include CD25, without internaliza-
tion of caspase-3 [71]. These differences between IL-2
signaling versus internalization of the fusion protein
underlie selective induction of apoptosis in effector
cells (including CD252 subsets) and expansion of sup-
pressor cells. In contrast, IL2-cas has proven effective
in the killing of malignant cell lines expressing the IL-2
receptor without inducing proliferation (S. Yarkoni,
unpublished data). Current experimental evidence in-
dicates a retained antileukemia effect of T cells in the
presence of IL2-cas in vitro and preserved GVT activ-
ity of selectively depleted T cells in vivo.
Robust expansion under lymphopenic conditions
generates dominant fractions of 50%-60%
CD41FoxP31 T cells in the lymph nodes of long-
term survivors. Expansion of this subset is mediated
by several mechanisms. First, IL2-cas spares
CD41FoxP31 T cells during short [38] and extended
periods of incubation. Second, the heterogeneous
CD252FoxP31 subset is endowed with suppressive
activity, as demonstrated by inhibition of T cell prolif-
eration in vitro, and includes Treg progenitors that ex-
pand in the periphery without obligatory thymic
priming [40]. Third, TCR engagement is essential to
initiate Treg proliferation but is not required to
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mandatory to sustain suppression and may promote
cycling [71-73]. Sustained engagement of host
antigens provides a strong proliferative stimulus, and
consequently Treg clones with antigen-specificity
have an expansion advantage [74]. Fourth, cytokine
environments created by radiation-induced lympho-
penia and LPS-mediated activation foster homeostatic
and spontaneous expansion [68]. Rebound of
CD41CD251FoxP31 Tregs accounting for 35% of
the CD41 subset in long-term survivors treated
in vivo and 10% of the CD41 subset in recipients of
IL2-cas–pretreated cells is the result of homeostatic
expansion of primed Treg precursors under lympho-
penic conditions in response to radiation-induced lym-
phopenia, cytokines, GVH reactivity, and LPS
stimulation [75,76].
The mechanism of IL2-cas–mediated immunomo-
dulation includes both deletional and proliferative ac-
tivities, with distinct effects on various cell subsets
characterized by different levels of the IL-2 receptor,
sensitivity to caspase-induced apoptosis, and IL-2–
stimulated proliferation. The evolving scenario delin-
eated by our data suggests that CD252FoxP31 Treg
precursors egress from the spleen and are found in in-
creasing numbers in the lymph nodes. CD41FoxP31
T cells resistant to IL2-cas–mediated apoptosis are in-
duced into rapid cycling and consequently expand
robustly under lymphopenic conditions, a process asso-
ciated with acquisition of the CD251 phenotype. The
inflammatory process underlying GVHD is positively
affected by immunomodulation, which enhances sup-
pressor mechanisms that persist not only when cells
are treated ex vivo, but also when the donors are immu-
nomodulated [49,77-79]. Although specific targeting of
GVHDeffectors remains to be optimized further, IL2-
cas has 2 particular advantages that maintain continued
remission after discontinuation of therapy: enhanced
Treg activity and prevention of effector/memory T
cell development. Combined selective pretransplanta-
tion depletion and posttransplantation GVHD
prophylaxis by IL2-cas has the potential to obviate
less specific approaches that impair engraftment, delay
immune reconstitution, and deplete Treg subsets.ACKNOWLEDGMENTS
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